KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in IntangiblesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Astrazeneca (AZN) over the last 15 years, with Q4 2025 value amounting to $3.2 billion.

  • Astrazeneca's Cash from Operations fell 1725.81% to $3.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $18.7 billion, marking a year-over-year increase of 1765.89%. This contributed to the annual value of $18.7 billion for FY2025, which is 1765.89% up from last year.
  • Per Astrazeneca's latest filing, its Cash from Operations stood at $3.2 billion for Q4 2025, which was down 1725.81% from $6.2 billion recorded in Q3 2025.
  • Astrazeneca's 5-year Cash from Operations high stood at $6.2 billion for Q3 2025, and its period low was $1.6 billion during Q2 2021.
  • Its 5-year average for Cash from Operations is $3.5 billion, with a median of $3.4 billion in 2023.
  • In the last 5 years, Astrazeneca's Cash from Operations surged by 20816.58% in 2021 and then plummeted by 1725.81% in 2025.
  • Quarter analysis of 5 years shows Astrazeneca's Cash from Operations stood at $2.2 billion in 2021, then increased by 2.59% to $2.2 billion in 2022, then rose by 25.34% to $2.8 billion in 2023, then surged by 40.9% to $3.9 billion in 2024, then decreased by 17.26% to $3.2 billion in 2025.
  • Its Cash from Operations stands at $3.2 billion for Q4 2025, versus $6.2 billion for Q3 2025 and $4.8 billion for Q2 2025.